Neuland Laboratories Ltd. (BSE: 524558) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹26,836 Cr, it ranks #311 by market cap among the 6,197 Indian listed companies on FinBizNet, and #15 of 86 in Medicinal Chemicals and Botanical Products. At ₹21,100.00 (as of 16 Nov 2026), the share price is 12.9% below its 52-week high of ₹24,225.00 and 83.5% above its 52-week low of ₹11,500.00. The share price is up 18.2% over one year and down 9.2% over three months.
| Current Price | ₹21,100.00 |
|---|---|
| Market Cap | ₹26,836 Cr |
| BSE Code | 524558 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 73.6 |
| Return on Equity | 21.42% |
| Return on Assets | 11.94% |
| 52-Week Range | ₹11,500.00 – ₹24,225.00 |
| 1-Year Price Change | +18.2% |
| 3-Month Price Change | -9.2% |
| Beta (1Y) | 0.89 |
| Dividend Yield | 0.16% |
| Headquarters | Hyderabad, Telangana |
| Website | www.neulandlabs.com |
| Revenue | ₹450 Cr |
|---|---|
| Net Profit | ₹52 Cr |
| Net Margin | 11.5% |
| EPS (Basic) | ₹40.24 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Neuland Laboratories Ltd. reported revenue of ₹450 Cr in Q2 FY27, down 12.6% from ₹514 Cr in Q2 FY26 and down 29.9% from ₹642 Cr in Q1 FY27. It posted a net profit of ₹52 Cr for the quarter, against a net profit of ₹97 Cr in Q2 FY26 (down 46.7%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹293 Cr (Q1 FY26) to ₹776 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹450 Cr | ₹52 Cr | 11.5% |
| Q1 FY27 | ₹642 Cr | ₹148 Cr | 23.0% |
| Q4 FY26 | ₹776 Cr | ₹213 Cr | 27.4% |
| Q3 FY26 | ₹440 Cr | ₹41 Cr | 9.2% |
| Q2 FY26 | ₹514 Cr | ₹97 Cr | 18.8% |
| Q1 FY26 | ₹293 Cr | ₹14 Cr | 4.7% |
| Q4 FY25 | ₹328 Cr | ₹28 Cr | 8.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 32.26% of Neuland Laboratories Ltd.'s shares as of Sept 2026, against 32.64% in Sept 2025 (−0.38 percentage points). Delivery averaged 49.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
1. Segment Adjustment-This segment engages in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs) for the generic market; and provision of custom manufacturing solutions to develop and manufacture APIs on an exclusive basis primarily for innovators. 2. Manufacture and Sale of Active Pharmaceutical Ingredients and Allied Services-0
1. Manufacture and Sale of Active Pharmaceutical Ingredients and Allied Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Neuland Laboratories Ltd. | ₹26,836 Cr | 73.6 | 21.42% | ₹450 Cr | +18.2% |
Listed by market capitalisation. Ratios are shown for context only.
Neuland Laboratories Ltd. is trading at ₹21,100.00, with a market capitalisation of ₹26,836 Cr.
Neuland Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Neuland Laboratories Ltd. has a P/E of 73.6 and a return on equity of 21.42%.
Neuland Laboratories Ltd. is listed on the BSE under the scrip code 524558.
Neuland Laboratories Ltd.'s share price is up 18.2% over one year and down 9.2% over three months. Its 52-week range is ₹11,500.00 to ₹24,225.00.
In Q2 FY27, Neuland Laboratories Ltd. reported revenue of ₹450 Cr and net profit of ₹52 Cr, with basic EPS of ₹40.24 (consolidated, parsed from the company's exchange filing).
Neuland Laboratories Ltd. reported revenue of ₹450 Cr in Q2 FY27, down 12.6% from ₹514 Cr in Q2 FY26 and down 29.9% from ₹642 Cr in Q1 FY27.
Promoters held 32.26% of Neuland Laboratories Ltd.'s shares as of Sept 2026, against 32.64% in Sept 2025 (−0.38 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.